Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Oral Anti Diabetic Agents in the Hospital

The randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin

diabetic ketoacidosis
hypoglycemia
insulin
continuous glucose monitoring
antidiabetic agents
  • 10 views
  • 23 Aug, 2020
  • 3 locations
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

GLP-1 receptor agonists (GLP-1 RA) is group of antidiabetic agents very effective in lowering the plasma glucose concentration in T2DM patients . Currently there are several agents approved for

semaglutide
sglt2
antidiabetic agents
glucagon
plasma glucose
  • 0 views
  • 27 Jul, 2020
  • 1 location
PIoglitazone for PrEvention of Restenosis in Diabetic Patients

stenting. Thiazolidinediones (TZDs), like pioglitazone (pio) or rosiglitazone, are a novel class of oral antidiabetic agents currently used to treat patients with type 2 diabetes mellitus

arterial disease
stent thrombosis
insulin
type 2 diabetes mellitus
thiazolidinediones
  • 27 views
  • 07 Nov, 2020
  • 1 location
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

gliclazide
  • 3 views
  • 08 Nov, 2020
  • 1 location
Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

Investigators aim is to conduct an RCT to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion. The patients will be randomly allocated to metformin or placebo treatment for 4 months

metformin
insulin
incretin
diabetes
  • 2 views
  • 23 Feb, 2020
  • 1 location
The Effects of Empagliflozin on Arterial Wall Characteristics

Introduction: Diabetes mellitus is characterized by impaired arterial function and high incidence of cardiovascular events. Metformin and most recent antidiabetic groups of drugs, SGLT2 inhibitors, were in previous studies shown to reduce cardiovascular events. Until now, direct effect of empagliflozin on arterial function and its comparison to metformin was not …

metformin
empagliflozin 25 mg
diabetes
type 2 diabetes mellitus
antidiabetic agent
  • 4 views
  • 08 Nov, 2020
  • 1 location
Dapagliflozin Plus Pioglitazone in T1DM

Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120 patients with type 1 diabetes who otherwise are healthy constitute the study population. After screening, eligible subjects …

hemoglobin a1c
c-peptide
ketoacidosis
dapagliflozin
hypoglycemia
  • 51 views
  • 02 Sep, 2020
  • 1 location
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Background The drug Jardiance treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood. The body makes ketones when it does not have enough glucose for fuel. The brains of many people with age-related diseases like Alzheimer s do …

  • 84 views
  • 02 Jan, 2021
  • 1 location
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has …

SARS
type 2 diabetes mellitus
insulin
angiotensin converting enzyme
covid-19
  • 20 views
  • 07 Oct, 2020
  • 1 location
Dipeptidyl Peptidase-IV Inhibitors Risk Factor for Development of Bullous Pemphigoid?

(DPP4) inhibitors, also known as gliptins, have been reported. DPP4 inhibitors are oral antidiabetic agents prescribed to patients with type 2 diabetes, as monotherapy, in combination with other oral

  • 2 views
  • 08 Nov, 2020
  • 1 location